The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 608-613

  Gremmel, Thomas ^a   Kopp, Christoph W ^a   Seidinger, Daniela ^a   Giurgea, Georgiana Aura ^a   Koppensteiner, Renate ^a   Steiner, Sabine ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aspirin; Clopidogrel; Monocyte platelet aggregates; Platelet function tests

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CD14 ANTIGEN; CLOPIDOGREL; GLYCOPROTEIN IB ALPHA; PADGEM PROTEIN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CAROTID ARTERY SURGERY; CONTROLLED STUDY; CORONARY STENT; FEMALE; FLOW CYTOMETRY; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REFERENCE VALUE; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIGENS, CD14; ARACHIDONIC ACID; ASPIRIN; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MONOCYTES; P-SELECTIN; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; STENTS; TICLOPIDINE;

EID: 70450277303     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.037     Document Type: Article

References (34)

1. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., and Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104 (2001) 1533-1537
2. Furman M.I., Barnard M.R., Krueger L.A., et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38 (2001) 1002-1006
3. Brambilla M., Camera M., Colnago D., et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol 28 (2008) 947-953
4. Kalsch T., Elmas E., Nguyen X.D., et al. Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation. Basic Res Cardiol 102 (2007) 460-466
5. Danenberg H.D., Kantak N., Grad E., et al. C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol 78 (2007) 246-252
6. Gawaz M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 (2005) 3378-3384
7. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
8. Braun O.O., Johnell M., Varenhorst C., et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 100 (2008) 626-633
9. Frelinger III A.L., Jakubowski J.A., Li Y., et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost 98 (2007) 192-200
10. Frelinger III A.L., Jakubowski J.A., Li Y., et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 6 (2008) 359-365
11. Harding S.A., Sarma J., Din J.N., et al. Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 92 (2006) 1335-1337
12. Storey R.F., Judge H.M., Wilcox R.G., and Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 88 (2002) 488-494
13. Heitzer T., Rudolph V., Schwedhelm E., et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 26 (2006) 1648-1652
14. Graff J., Harder S., Wahl O., Scheuermann E.H., and Gossmann J. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther 78 (2005) 468-476
15. Klinkhardt U., Bauersachs R., Adams J., et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 73 (2003) 232-241
16. Geisler T., Langer H., Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
17. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
18. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5 (2007) 1630-1636
19. Steiner S., Speidl W.S., Pleiner J., et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111 (2005) 1841-1846
20. Cattaneo M., Lecchi A., Zighetti M.L., and Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 92 (2007) 694-697
21. Linnemann B., Schwonberg J., Mani H., Prochnow S., and Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 6 (2008) 677-683
22. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
23. Chen W.H., Cheng X., Lee P.Y., et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120 (2007) 631-635
24. Siller-Matula J.M., Lang I., Christ G., and Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52 (2008) 1557-1563
25. Gremmel T., Steiner S., Seidinger D., et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 101 (2009) 333-339
26. Frere C., Cuisset T., Quilici J., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 98 (2007) 838-843
27. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46 (2005) 1820-1826
28. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
29. Paniccia R., Antonucci E., Gori A.M., et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 5 (2007) 1839-1847
30. Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154 (2007) 221-231
31. Diacovo T.G., deFougerolles A.R., Bainton D.F., and Springer T.A. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest 94 (1994) 1243-1251
32. Chavakis T., Santoso S., Clemetson K.J., et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem 278 (2003) 45375-45381
33. Simon D.I., Chen Z., Xu H., et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 192 (2000) 193-204
34. McEver R.P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 86 (2001) 746-756